NCT04927884
Breast Cancer Type: Triple Negative
Hormone Mutations:
Other Mutations:
Breast Cancer Tissue:
Recruitment Status: Recruiting
Phase 1|Phase 2
Drug Category: Therapeutic Antibody, Immunotherapy, Chemotherapy
Key Eligibility Criteria:
Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: Brain
Additional Notes:
Exclusions: Patients who previously received or are currently receiving treatment with Trodelvy/sacituzumab govitecan
https://ClinicalTrials.gov/show/NCT04927884